title: The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer.
abstract: Dendritic cell (DC) mono-immunotherapy has not been successful so far in ovarian cancer. The addition of a toll-like receptor (TLR) agonist has the potential to boost the innate immune system, in addition to the adoptive immune response initiated by DCs.
  
  
  
  ID8-fLuc C57BL/6 mice were injected with DCs loaded with hypericin-based photodynamic therapy-treated tumor lysate. A TLR4 agonist [lipopolysaccharide (LPS)] was administered by different schedules). After two and three DC vaccinations, immune analysis was performed.
  
  
  
  There was no survival benefit from therapy with TLR4 agonist. Moreover, if LPS administrations started one week after tumor inoculation, the overall survival was even worse than that of untreated controls. Immune analyses revealed an intratumoral increase in natural killer cells and a decrease in regulatory T-cells, but an immunosuppressive signature in the ascites.
  
  
  
  Addition of LPS as an adjuvant to DC immunotherapy of ovarian cancer does not result in survival benefit.
authors: Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.
authors: Eva
authors: E
authors: Vindevogel
authors: Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.|Department of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
authors: Thaïs
authors: T
authors: Baert
authors: Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.|Department of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
authors: Anaïs
authors: A
authors: VAN Hoylandt
authors: Department of Development and Regeneration, Organ Systems, KU Leuven, Leuven, Belgium.
authors: Godelieve
authors: G
authors: Verbist
authors: Department of Imaging and Pathology, Biomedical MRI/MoSAIC, KU Leuven, Leuven, Belgium.
authors: Greetje
authors: G
authors: Vande Velde
authors: Laboratory for Cell Death Research and Therapy (CDRT), Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
authors: Abhishek D
authors: AD
authors: Garg
authors: Laboratory for Cell Death Research and Therapy (CDRT), Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
authors: Patricia
authors: P
authors: Agostinis
authors: Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.|Department of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
authors: Ignace
authors: I
authors: Vergote
authors: Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, ImmunOvar Research Group, KU Leuven, Leuven, Belgium an.coosemans@gmail.com.|Department of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
authors: A N
authors: AN
authors: Coosemans
mesh_terms: D000818:Animals; D005260:Female; D007167:Immunotherapy; D051379:Mice; D008810:Mice, Inbred C57BL; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D051197:Toll-Like Receptor 4 / Q000819:agonists*
chemical_list: C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4
keywords: DC; Dendritic cell; LPS; TLR4; immunotherapy; mouse; ovarian cancer; toll-like receptor